Living slideset on optimal management of CLL during the COVID-19 pandemic will be continually up-to-date as the situation evolves and new data emerge
New from EULAR 2020: risk of JAKi, IL-6i, abatacept vs TNFi discontinuation among patients with rheumatoid arthritis, as reported by Clinical Care Options (CCO)
From EULAR 2020, new safety analysis of risk for thromboembolic events with tofacitinib and baricitinib in RA, reported by Clinical Care Options (CCO)
From EULAR 2020, new data from RABBIT trial assessing risk of herpes zoster infection among RA patients by class of DMARD, as reported by CCO
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.